Share this post on:

Product Name: EIF4E2 antibody [N1C3]
Applications: IHC-P, WB
Predicted Target Size: 28 kDa (note)
Positive Controls: Target recombinant protein
Form Supplied: Liquid
Concentration: 1 mg/ml (Please refer to the vial label for the specific concentration)
Purification: Purified by antigen-affinity chromatography.
Full Name: eukaryotic translation initiation factor 4E family member 2
Background: Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation of protein synthesis and facilitates ribosome binding by inducing the unwinding of the mRNAs secondary structures.
Synonyms: 4E-LP antibody, 4EHP antibody, EIF4EL3 antibody, IF4e antibody, EIF4E2 antibody, mRNA cap-binding protein 4EHP antibody, eIF4E type 2 antibody, eIF4E-like protein 4E-LP antibody, eukaryotic translation initiation factor 4E-like 3 antibody, eIF4E-like cap-binding protein antibody, eukaryotic translation initiation factor 4E member 2 antibody, mRNA cap-binding protein type 3 antibody, eIF-4E type 2 antibody, eukaryotic translation initiation factor 4E type 2 antibody, eukaryotic translation initiation factor 4E homologous protein antibody, eukaryotic translation initiation factor 4E family member 2 antibody
Cellular Localization:
CAS NO: 848344-36-5
Product: AT7867
Host: Rabbit
Clonality: Polyclonal
Isotype: IgG
Immunogen: Recombinant protein encompassing a sequence within the center region of human EIF4E2. The exact sequence is proprietary.
Antigen Species: Human
Species Reactivity: Human, Mouse
Conjugation: Unconjugated
Storage Buffer: 0.1M Tris, 0.1M Glycine, 10% Glycerol (pH7). 0.01% Thimerosal was added as a preservative.
Storage Instruction: Keep as concentrated solution. Aliquot and store at -20ÂșC or below. Avoid multiple freeze-thaw cycles.
Notes: For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Specificity:
PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/20081850?dopt=Abstract

Share this post on: